$1.67
4.38% today
Nasdaq, Sep 03, 08:12 pm CET
ISIN
US03835L1089
Symbol
APVO

Aptevo Therapeutics Inc Stock price

$1.60
-0.99 38.22% 1M
-60.20 97.41% 6M
-84.60 98.14% YTD
-264.80 99.40% 1Y
-116,234.34 100.00% 3Y
-267,316.00 100.00% 5Y
-3,646,718.40 100.00% 10Y
-3,646,718.40 100.00% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.04 2.44%
ISIN
US03835L1089
Symbol
APVO
Industry

Key metrics

Basic
Market capitalization
$5.3m
Enterprise Value
$-4.2m
Net debt
positive
Cash
$9.4m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.8
Financial Health
Equity Ratio
30.5%
Return on Equity
-504.7%
ROCE
-226.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-24.0m | -
EBIT
$-24.3m | $-23.4m
Net Income
$-24.0m | $-1.0b
Free Cash Flow
$-24.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.8% | -
EBIT
6.3% | 6.5%
Net Income
3.7% | -4,235.4%
Free Cash Flow
0.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-32.5
FCF per Share
$-7.6
Short interest
1.6%
Employees
37
Rev per Employee
$0.0
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
6% 6%
-
- Research and Development Expense 14 14
6% 6%
-
-24 -24
6% 6%
-
- Depreciation and Amortization 0.26 0.26
41% 41%
-
EBIT (Operating Income) EBIT -24 -24
6% 6%
-
Net Profit -24 -24
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
21 days ago
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors SEATTLE, WA / ACCESS Newswire / August 13, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company...
Neutral
Accesswire
23 days ago
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for...
Neutral
Accesswire
3 months ago
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrant...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 37
Founded 2016
Website aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today